E-Cigarette Firm Targets Harm Reduction In Therapeutic Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
CN Creative’s plan to include harm reduction with smoking cessation in claims for its Nicadex electronic cigarette was key to Advent Life Sciences investing in the firm, which is prepared to ask U.K. regulators for approval this summer before applying in the U.S.